The dose-dependency of the effects of 2 methyl 3 (phenylaminomethyl)-1h-quinolin-4 one – a promising antidepressant with nootropic properties
DOI:
https://doi.org/10.24959/cphj.16.1408Keywords:
2 methyl-3 (phenylaminomethyl)-1H-quinolin-4-one, dose-dependency, tail suspension test, passive avoidance testAbstract
The object of the study is 2‑methyl-3‑(phenylaminomethyl)-1H-quinolin-4-one. According to the results of the screening of a series of 3-(N-R,R’-aminomethyl)-2-methyl-1H-quinolin-4-ones it has been proven that in the dose of 100 mg/kg it has the high antidepressant activity in tail suspension test (TST) and prevents scopolamine-induced amnesia development in passive avoidance test (PAT). The present post-screening study was carried out with the purpose of dose-dependency detalization using the doses of 5, 50, 100 and 150 mg/kg in TST and PAT after scopolamine-induced amnesia. The comparison of experimental results of screening and post-screening studies has allowed revealing relationships between the activity and the amount of the substance introduced in a wide range of doses. According to the results of TST in both studies it has been concluded that the only dose of 2‑methyl-3‑(phenylaminomethyl)-1H-quinolin-4-one, which provides a considerable antidepressant activity, is 100 mg/kg. The comparison of PAT results in screening and post-screening studies has been shown that in almost all doses studied, except 5 mg/kg, 2‑methyl-3‑(phenylaminomethyl)-1H-quinolin-4-one significantly attenuate the amnesic effect of scopolamine. Therefore, the effective dose of 2‑methyl-3‑(phenylaminomethyl)-1H-quinolin-4-one for in-depth studies is 100 mg/kg with both activities (antidepressant and anti-amnesic) at their maximum.
References
Зубков В.А., Гриценко И.С., Таран С.Г. и др. // ЖОФХ. – 2005. – Т. 3, №2 (10). – С. 23-27.
Коваленко В.М. // Фармакол. та лікарська токсикол. – 2009. – Т. 12, №5. – 2009. – С. 56-61.
Лакин Г.Ф. Биометрия : Учеб. пособие для биол. спец. вузов. – М.: Высш. шк., 1990. – 352 с.
Настанова СТ-Н МОЗУ 42-6.0:2008. Лікарські засоби. Належна лабораторна практика (видання офіційне) / О. Стефанов, Т. Бухтіарова, В. Коваленко та ін. – К.: Моріон, 2009. – С. 37-68.
Радионова К.С., Бельник А.П., Островская Р.У. // Бюл. эксперим. биол. и медицины. – 2008. – Т. 146, №1. – С. 65-68.
Руководство по проведению доклинических исследований лекарственных средств. Ч. І / Под ред. А.Н.Миронова. – М.: Гриф и К, 2012. – 944 с.
Штриголь С.Ю., Зубков В.О., Гриценко І.С. та ін. // Клінічна фармація. – 2010. – Т. 14, №1. – С. 35-38.
Bammer G. // Neurosci. and Biobehavioral Rev. – 1982. – Vol. 6, №3. – P. 247-296.
Can A., Dao D.T., Terrillion C.E. et al. // J. of Visualized Experiments. – 2012. – Vol. 59. – e3769.
Deacon R.M. // Nature Protocols. – 2006. – Vol. 1, №2. – P. 936-946.
Drug Discovery and Evaluation: Pharmacological Assays / H.G.Vogel (ed.). – 3-rd Ed., Springer, Berlin, Heidelberg, New York, 2008. – P. 902-906.
Ebert U., Kirch W. // Eur. J. Clin. Invest. – 1998. – Vol. 28, №11. – P. 944-949.
Steru L., Chermat R., Thierry B., Simon P. // Psychopharmacol. (Berl). – 1985. – Vol. 85. – P. 367-370.
Downloads
Published
Issue
Section
License
Copyright (c) 2016 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
